| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 50.2 | 44.9 | 48.9 |
| Other income | 2.2 | 2.9 | 6.7 |
| Total income | 52.4 | 47.8 | 55.6 |
| Profit before exceptional items & tax | 3.3 | 3.9 | 9.4 |
| Profit before tax | 3.3 | 3.9 | 9.4 |
| Net profit | 1.4 | 2.0 | 8.0 |
| Operating margin | 6.3% | 8.2% | 16.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -82.50% |
|---|---|
| Net profit, quarter on quarter | -30.00% |
| Revenue, year on year | +2.70% |
| Operating profit, year on year | -59.30% |
| Operating profit, quarter on quarter | +10.00% |
BSE results filing, NSE: KILITCH. Figures extracted from the filing.
Kilitch Drugs(I) Ltd: key numbers
- Share price
- ₹195.25
- Market cap
- ₹682.6 Cr
- Revenue (annual)
- ₹235.5 Cr
- Net profit (annual)
- ₹30.17 Cr
- P/E (TTM)
- 22.7×Sector 43.0×
- Promoter holding
- 63.77%+0.00% QoQ
- FII holding
- 0.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kilitch Drugs(I) Ltd
All →Kilitch Drugs(I) Board Meeting Date
Kilitch Drugs will hold a board meeting on 6 November 2026 to consider unaudited quarterly and half-year results. The trading window stays closed until 48 hours after disclosure.
Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs' EGM notice seeks shareholder approval for selling its Ethiopian material subsidiary and converting subsidiary debt into equity. It also proposes two independent director appointments.
Kilitch Drugs(I) Merger & Restructuring Worth ₹131.6 Cr
Kilitch Drugs will divest its entire Ethiopian subsidiary stake to HarmeeCare for US$14 million (~₹131.6 Crore). Proceeds will fund debt repayment and Pen plant expansion.
- Value
- ₹131.6 Cr
Kilitch Drugs(I) Merger & Restructuring Worth ₹120.8 Cr
Kilitch Drugs will divest its 100% stake in subsidiary Kilitch Estro Biotech PLC for USD 12.855 million (approx. ₹120.84 Crore).
- Value
- ₹120.8 Cr
- From
- HarmeeCare Pharmaceuticals
Kilitch Drugs(I) Management Change
Kilitch Drugs' Non-Executive Independent Director Mr. Venkita Subramanian Rajan resigned effective 21 Oct 2026. He also stepped down from the Audit, NCR, and SRC Committees citing personal commitments.
Kilitch Drugs(I) Other Announcement
Kilitch Drugs (India) Limited submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2026.